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Abstract 
Review on t(4;17)(q12;q21) FIP1L1/RARA, with 
data on clinics, and the genes implicated. 
Clinics and pathology 
Disease 
Juvenile myelomonocytic leukemia (JMML) and 
acute promyelocytic leukemia (APL) 
Epidemiology 
Only 3 cases reported; a 1 year old male patient 
with JMML (Buijs and Bruin, 2007) and 2 females 
aged 77 and 90 years diagnosed with APL (Kondo 
et al., 2008; Menezes et al., 2011). 
Morphology of JMML. Bone marrow smears were stained 
with May-Grünwald-Giemsa and shown at 1000-fold 
magnification. Bd=band, Bl=myelomonoblast, 
Eb=erythroblast, Mc=myelocyte, Mo=monocyte, 
Pm=promyelocyte, Se=segmented neutrophylic 
granulocyte. 
Evolution 
Sole anomaly at diagnosis in a JMML patient that 
evolved to complex karyotype at relapse: 45,XY,-
4,t(4;17)(q12;q21), add(5)(p15),del(7)(q22), -9, -
16, -17, +3mar[19]/46,XY[5].  
Karyotype of patients with APL: 
47,XX,t(4;17)(q12;q21),+8 (Menezes et al., 2011) 
and 44,X,add(X)(p?),-2,t(4;17)(q12;q21),-4,-16 
(Kondo et al., 2008). 
Prognosis 
Unknown, as only rare cases reported.  
The patient with JMML succumbed after two SCT. 
In patients with APL, FIP1L1-RARA had an ATRA 
response similar to that of PML-RARA. 
Cytogenetics 
Partial GTG-banded karyotype of t(4;17)(q12;q21). 
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FISH analysis using probe LSI RARA DC resulting in a fusion signal on chromosome 17 band q21, with a split 5' RARA red 
signal on der(17) and a 3' RARA green signal on der(4) (left panel). FISH analysis narrowing the 4q12 breakpoint to the proximity 
of FIP1L1 by using 4q12 specific BAC probes RP11-120K16/RP11-317M1 with a fusion signal on chromosome 4 band q12, with 




In APL 17q21 RARA frequent rearrangement in: 
t(15;17)(q22;q21), fused with PML; in related 
translocations, rarely observed, involve a common 
breakpoint in 17q21, within RARA, fused with 
different partners, in: t(11;17)(q23;q21), fusion 
with PLZF, t(5;17)(q35;q12), fusion with NPM1, in 
t(11;17)(q13;q21), fusion with NUMA and in 
dup(17)(q12q21), fusion with Stat5b. In 
myeloproliferative disease CEL (Chronic 
eosinophilic leukemia) 4q12 FIP1L1 
rearrangement: fusion to PDGFRA due to 800 Kb 
interstitial deletion. 






FIP1L1 is a subunit of the cleavage and 
polyadenylation specific factor (CPSF) complex 
that binds to U-rich elements via arginine-rich RNA 






Wide expression; nuclear receptor; binds specific  
DNA sequences: HRE (hormone response 
elements); ligand and dimerization domain; role in 
growth and differentiation. 




In-frame fusion of exon 15 of FIP1L1 to exon 3 of 
RARA (Buijs and Bruin, 2007; Kondo et al., 2008) 
or with exon 13 of the FIP1L1 gene (Menezes et al., 
2011). 
Transcript 
5'FIP1L1-3'RARA and 5'RARA-3'FIP1L1. 
Fusion protein 
Description 
The fusion mRNA would encode a 832 amino acids 
FIP1L1/RARA chimeric protein containing the 428 
amino-terminal amino acids of FIP1L, including the 
FIP homology domain and 403 carboxyl-terminal 
amino acids of RARA, including the DNA and 
ligand binding domains, with replacement of 
FIP1L1 amino acid 429 (Valine) and RARA amino 
acid 60 (Threonine) into an Alanine. 
Oncogenesis 
All known chimeric RARA fusion proteins provide 
additional homodimerization motifs, promoting 
formation of chimeric homodimers and thereby 
removing requirement of RXR for RARA to bind 
DNA.  
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FIP1L1: Conserved FIP domain; RARA; DBD DNA binding domain, LBD ligand binding domain. 
 
 
The homodimerization ability of RARA fusion 
proteins is critical for leukemic transformation. 
Recently, it was shown in a murine system that 
retroviral transduced FIP1L1/PDGFRA mediated 
transformation in vitro and in vivo, is FIP1L1 
independent and results from disruption of the 
autoinhibitory JM domain of PDGFRA.  
However, observations using retroviral transduced 
FIP1L1/PDGFRA and FIP1L1/PDGFRA with an 
N-terminal deletion of the FIP1L1 moiety showed 
differences with respect to cytokine-independent 
colony formation and activation of multiple 
signalling pathways in human primary 
hematopoietic precursor cells, indicating that 
FIP1L1 contributes to FIP1L1/PDGFRA resulting 
in a myeloproliferative phenotype.  
Therefore the function of the FIP1L1 moiety 
remains to be resolved 
To be noted 
Note 
We report on reciprocal FIP1L1/RARA fusion 
transcripts resulting from a novel t(4;17)(q12;q21) 
in a case of juvenile myelomonocytic leukemia 
(JMML).  
JMML is a pediatric myeloproliferative disease 
(MPD), characterized by proliferation of 
granulocytic and monocytic lineages.  
17q12 RARA was demonstrated to be involved in 
t(15;17)(q22;q21), resulting in a PML/RARA 
fusion transcript.  
PML/RARA t(15;17) is the hallmark of acute 
promyelocytic leukemia (APL), characterized by a 
differentiation arrest of abnormal promyelocytes.  
Variant rearrangements involving 17q21 RARA in 
APL and APL-like (APL-L) disease are 
PLZF/RARA t(11;17)(q23;q21), NPM1/RARA 
t(5;17)(q35;q21), NUMA/RARA 
t(11;17)(q13;q21), STAT5b/RARA der(17) and 
t(3;17)(p25;q21). 4q12 FIP1L1 is fused to 
PDGFRA as a result of a del(4)(q12q12) in 
myeproliferative disorder CEL. 
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